Before starting his current role as CEO of the St. Hope Foundation in Houston, Robert Goodie served as executive director of the Donald R. Watkins Memorial Foundation. In his work with St. Hope, Robert Goodie oversees several health care delivery and prevention programs focused on chronic and communicable illnesses such as hepatitis C and HIV. The prophylactic drugs PrEP and PEP have greatly advanced progress towards HIV elimination. PrEP is a daily pill that can reduce the likelihood of developing HIV. PrEP is recommended for people who have an elevated risk of contracting HIV. This includes people with HIV positive partners, people with multiple sexual partners, or people who inject drugs using shared needles. When taken as recommended and combined with medical monitoring, PrEP can reduce HIV transmission through sex by 99 percent and through intravenous drug use by 70 percent. On the other hand, PEP is a short-term prophylactic intended for people who have been exposed to HIV. PEP is most effective when started less than three days after exposure. A PEP course is prescribed for 28 days.